

## Disclosures

### Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Vascular	Speaker's Bureau	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Abbott Vascular	Consultant Fees/Honoraria	Significant (>= \$5,000)	
Biotronik	Speaker's Bureau	Modest (< \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Boston Scientific	Research/Research Grants	Significant (>= \$5,000)	
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Cleerly Health	Stock	None (\$0)	
CSI	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Elsevier	Consultant Fees/Honoraria	Significant (>= \$5,000)	
GE Healthcare	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
GE Healthcare	Research/Research Grants	Significant (>= \$5,000)	
Haemonetics	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Hippocrates LLC	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	
IMDS	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Medtronic	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
MHI Ventures	Stock	None (\$0)	
Orbus Neich	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
SIS Medical	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Teleflex	Speaker's Bureau	Modest (< \$5,000)	

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (7)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American Heart Association	Other - <i>associate editor, Circulation</i>	Significant (>= \$5,000)	
Cardiovascular Innovations Foundation	Officer, Director, Trustee, or other Fiduciary Role	Significant (>= \$5,000)	<a href="#">Invasive CV Angio and Interventions</a>
Hippocrates LLC	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	
LifeLens Technologies	Ownership Interest/Partnership/Principal	None (\$0)	<a href="#">Invasive CV Angio and Interventions</a>
MHI Ventures	Ownership Interest/Partnership/Principal	Significant (>= \$5,000)	
Stallion Medical	Ownership Interest/Partnership/Principal	None (\$0)	<a href="#">Invasive CV Angio and Interventions</a>
TrueVue Inc	Ownership Interest/Partnership/Principal	None (\$0)	<a href="#">Invasive CV Angio and Interventions</a>

### Clinical Trial Enroller (23)

Trial Name	Trial Sponsor	Trial Funding Source
Xience 90	Abbott	
Xience 28	Abbott Laboratories	
Jostent HDE 1412-1 Registry	Abbott Laboratories	

Trial Name	Trial Sponsor	Trial Funding Source
ABT NG DES 48 Skypoint 48	Abbott Laboratories	
Shield II	Abbott Laboratories	
Illumien IV	Abbott Laboratories	
Themis	AstraZeneca Pharmaceuticals	
Bioflow VII	Biotronik	
Papyrus	Biotronik	
ECLIPSE	CSI	
Aegis II	CSL Behring	
Faraday	Faraday Pharmaceuticals	
PICANTE	Kardion	
Bionics	Medinol	
Resolute Onyx PAS	MEDTRONIC	
Vertis	Merck	
Sapphire 3	OrbusNeich	
Spire LDL	Pfizer Inc	
Recardio	Recardio	
R1500 --	Regeneron	
Disrupt CAD III	Shockwave Medical	
Pioneer III	Sinomed	
Ventrix CV-201	Ventrix	

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (2)

Year	Case Title	Represented	Description	Compensation
<i>Self</i>				
2012	review of case of left main disease	Defendant	expert testimony on a patient with left main disease	None (\$0)
2011	review of case of left main disease	Defendant	Reviewed a case of a patient with left main disease that presented with an acute coronary syndrome and subsequently developed cardiogenic shock and died.	None (\$0)

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 6/23/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement | Signed on 6/23/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo | Signed on 6/23/2025

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement | Signed on 6/23/2025

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.

